Empirical Finance’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $24.5M | Sell |
26,607
-44
| -0.2% | -$44.6K | 1.15% | 14 |
|
|
2025
Q4 | $28.6M | Sell |
26,651
-1,467
| -5% | -$1.4M | 1.37% | 11 |
|
|
2025
Q3 | $21.5M | Buy |
28,118
+459
| +2% | +$342K | 1.02% | 12 |
|
|
2025
Q2 | $21.6M | Buy |
27,659
+182
| +0.7% | +$141K | 1.13% | 12 |
|
|
2025
Q1 | $22.7M | Buy |
27,477
+302
| +1% | +$251K | 1.37% | 11 |
|
|
2024
Q4 | $21M | Sell |
27,175
-365
| -1% | -$302K | 1.21% | 13 |
|
|
2024
Q3 | $24.4M | Buy |
27,540
+644
| +2% | +$579K | 1.42% | 10 |
|
|
2024
Q2 | $24.4M | Sell |
26,896
-1,780
| -6% | -$1.42M | 1.52% | 8 |
|
|
2024
Q1 | $22.3M | Buy |
28,676
+964
| +3% | +$686K | 1.37% | 9 |
|
|
2023
Q4 | $16.2M | Buy |
27,712
+174
| +0.6% | +$102K | 1.13% | 14 |
|
|
2023
Q3 | $14.8M | Buy |
27,538
+2,654
| +11% | +$1.37M | 1.09% | 18 |
|
|
2023
Q2 | $11.7M | Buy |
24,884
+2,735
| +12% | +$1.15M | 0.9% | 20 |
|
|
2023
Q1 | $7.61M | Buy |
22,149
+1,114
| +5% | +$376K | 0.71% | 25 |
|
|
2022
Q4 | $7.7M | Buy |
21,035
+1,544
| +8% | +$547K | 0.8% | 23 |
|
|
2022
Q3 | $6.3M | Buy |
19,491
+3,087
| +19% | +$978K | 0.75% | 24 |
|
|
2022
Q2 | $5.32M | Buy |
16,404
+864
| +6% | +$259K | 0.68% | 28 |
|
|
2022
Q1 | $4.45M | Buy |
15,540
+1,582
| +11% | +$407K | 0.5% | 37 |
|
|
2021
Q4 | $3.85M | Buy |
13,958
+3,624
| +35% | +$919K | 0.46% | 40 |
|
|
2021
Q3 | $2.39M | Buy |
10,334
+546
| +6% | +$135K | 0.36% | 51 |
|
|
2021
Q2 | $2.25M | Buy |
9,788
+1,175
| +14% | +$236K | 0.37% | 51 |
|
|
2021
Q1 | $1.45M | Hold |
8,613
| – | – | 0.26% | 102 |
|
|
2020
Q4 | $1.45M | Buy |
8,613
+1,346
| +19% | +$201K | 0.26% | 102 |
|
|
2020
Q3 | $1.08M | Buy |
7,267
+1,416
| +24% | +$219K | 0.23% | 114 |
|
|
2020
Q2 | $961K | Buy |
5,851
+710
| +14% | +$109K | 0.25% | 110 |
|
|
2020
Q1 | $713K | Buy |
5,141
+1,733
| +51% | +$238K | 0.22% | 105 |
|
|
2019
Q4 | $448K | Buy |
3,408
+1,166
| +52% | +$135K | 0.11% | 145 |
|
|
2019
Q3 | $251K | Buy |
2,242
+37
| +2% | +$4.12K | 0.07% | 150 |
|
|
2019
Q2 | $244K | Sell |
2,205
-43
| -2% | -$5.06K | 0.07% | 143 |
|
|
2019
Q1 | $292K | Buy |
+2,248
| New | +$273K | 0.07% | 139 |
|
|
2018
Q4 | – | Sell |
-1,921
| Closed | -$206K | – | 157 |
|
|
2018
Q3 | $206K | Buy |
+1,921
| New | +$192K | 0.05% | 149 |
|
|
2018
Q2 | – | Sell |
-2,248
| Closed | -$292K | – | 172 |
|
|
2018
Q1 | $292K | Buy |
+2,248
| New | +$181K | 0.07% | 139 |
|
|
2017
Q1 | – | Sell |
-493
| Closed | -$37K | – | 353 |
|
|
2016
Q4 | $37K | Buy |
+493
| New | +$36.7K | 0.03% | 126 |
|
Other funds holding LLY
VCM
VPM
Empirical Finance's LLY Position: Q1 2026 in Review
Empirical Finance reduced its Eli Lilly (LLY) stake by 0.17% in Q1 2026, selling an estimated $44.6K and leaving 26,607 shares worth $24.5M. The position accounts for 1.15% of the portfolio, ranked #14.
Empirical Finance first reported a position in LLY in Q4 2016 and has held it in 32 quarters since. The position peaked at $28.6M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Empirical Finance held 26,607 shares of Eli Lilly worth $24.5M as of Q1 2026.
- Empirical Finance sold 44 Eli Lilly shares in Q1 2026, an estimated $44.6K.
- Eli Lilly made up 1.15% of Empirical Finance's portfolio in Q1 2026, its #14 holding.
- Empirical Finance first reported a position in Eli Lilly in Q4 2016 and has held it in 32 quarters since.
- Empirical Finance's Eli Lilly position peaked at $28.6M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Empirical Finance's 13F filing for Q1 2026, filed 14 May 2026.